JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics
Synopsis: Geoff Nosrati is the Chief Business Officer of Nutcracker Therapeutics, an early-stage company that is pioneering a revolutionary therapeutic development and manufacturing platform designe...
9 Tammi 202325min
133. Pharma & Profits, John LaMattina, former Pres. of R&D, Pfizer, Senior Partner, PureTech Health
Synopsis: John LaMattina is the former President of Global R&D at Pfizer and is currently a Senior Partner at PureTech Health. A self-proclaimed defender of the pharmaceutical industry, Dr. LaMattin...
4 Tammi 202333min
132. Targeting ferroptosis cell death for cancer and beyond, Luba Greenwood, CEO, Kojin Therapeutics
Synopsis: Luba Greenwood is the CEO of Kojin Therapeutics and Managing Partner of Dana Farber Cancer Institute Venture Fund. Kojin Therapeutics harnesses groundbreaking discoveries in cell state and ...
21 Joulu 202231min
131. Epigenetic approaches to rare diseases, Amber Salzman, CEO, Epic Bio
Synopsis: Amber Salzman is the CEO of Epic Bio, a company that develops therapies to dynamically control gene expression and treat complex diseases. Dr. Salzman started her career in big pharma at Gl...
14 Joulu 202224min
130. Breast cancer: targeted treatment options, Sean Bohen, President & CEO, Olema Oncology
Synopsis: Sean Bohen is the President and CEO of Olema Oncology, a company dedicated to developing targeted therapies for women with breast cancer. An oncologist by training, Dr. Bohen has a backgro...
7 Joulu 202222min
129. Progress in complex diseases: NASH, Long COVID, and beyond, Bill Hinshaw, Pres. & CEO, Axcella
Synopsis: Bill Hinshaw is the President and CEO of Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulat...
30 Marras 202226min
128. Treating rare neurological diseases & guiding mission, Jeremy Levin, Chairman & CEO, Ovid Tx
Synopsis: Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, a company that develops medicines to treat patients with rare neurological conditions, including epilepsies and seizure-related di...
23 Marras 202230min
127. Immuno-oncology landscape, Keith Flaherty, Dir. of Clin. Research, Mass General Cancer Center
Synopsis: Keith Flaherty is the Director of Clinical Research at Mass General Cancer Center and a Professor of Medicine at Harvard Medical School. Dr. Flaherty is a medical oncologist and has worked ...
16 Marras 202247min
